Neste trabalho, anticorpos anti-IgGh foram conjugados às nanopartículas de prata (NPAg) para detectar imunoglobulina G humana (IgGh). Um imunoensaio colorimétrico baseado na diminuição da agregação devido ao aumento da repulsão eletrostática após a interação ligante-alvo. A agregação é induzida pela variação da força iônica e uma mudança da coloração da suspensão coloidal de amarelo para vermelho pode ser observada. Na presença de IgGh, a agregação é inibida e a coloração da suspensão coloidal não se altera. As nanopartículas foram obtidas por meio de cinco procedimentos diferentes e caracterizadas por espectroscopia UV-Vis, espalhamento dinâmico de luz, difração de raios-X e microscopia eletrônica. Glicose e borohidreto de sódio foram utilizados como agentes redutores, enquanto CTAB e β-ciclodextrina foram utilizados como estabilizantes. Citrato de sódio foi utilizado como agente redutor e/ou estabilizante. Nanoesferas de carbono foram obtidas por tratamento hidrotérmico de uma solução aquosa de glicose e também foram utilizadas no preparo das nanopartículas. As nanopartículas foram funcionalizadas com ácido mercaptossuccínico e a conjugação ocorreu devido à interação entre grupos aminas e grupos carboxílicos ionizados, presentes no anticorpo e agente de acoplamento, respectivamente. A estabilidade dos conjugados e o efeito da adição de IgGh foram avaliados para todos os sistemas preparados. As nanopartículas de prata preparadas com borohidreto de sódio e citrato de sódio foram selecionadas para serem aplicadas no desenvolvimento do imunoensaio e as condições experimentais foram avaliadas. Em condições ótimas, observou-se uma correlação linear entre a diminuição da agregação do sistema (NPAg-anti-IgGh) e a concentração de IgGh (0 a 200 ng mL-1). O limite de detecção foi estimado em 25 ng mL-1. O método colorimétrico apresentou boa seletividade para a detecção de IgGh. Além disso, foi obtido um resultado satisfatório ao aplicar o método para determinação do fator IX de coagulação. Foi desenvolvido também um método para determinação de ATP baseado na agregação de nanopartículas de ouro. Aptâmeros foram utilizados como elemento de reconhecimento. Em princípio, o método pode ser aplicável à determinação de outros analitos, por meio da substituição do aptâmero utilizado neste trabalho pelo oligonucleotídeo específico para o alvo de interesse. / In this work, antibodies to human immunoglobulin G (anti-IgGh) were used in combination with silver nanoparticle (NPAg) to detect IgGh. A colorimetric immunoassay based on the decrease of aggregation due to increased electrostatic repulsion upon ligand-target interaction. Aggregation was induced by varying the ionic strength and the solution of NPAg-anti-IgGh shows obvious visible color change from yellow to red. In the presence of IgGh aggregation the nanoparticle is inhibited and coloration of the colloidal solution does not change. The nanoparticles were obtained using five different procedures and they were characterized by UV-Vis spectroscopy, dynamic light scattering, X-ray diffraction and electron microscopy. Glucose and sodium borohydride were used as reducing agent, as CTAB and β-cyclodextrin reagents were used as stabilizers. Sodium citrate was used as reducing and stabilizing agent. Carbon nanospheres were prepared by hydrothermal treatment of glucose and used in the preparation of NPAg. The nanoparticles were functionalized with dimercaptosuccinic acid and their conjugation occurred due to the interaction of positively charged amine groups and anionic groups (-COO-) present on the antibody and coupling agent. The stability of conjugates and the variation of aggregation in the presence of IgGh were evaluated for all systems. The NPAg prepared by sodium borohydride were selected for use in the immunoassay and the optimum conditions of the assay were investigated. Under the optimal conditions, the ration between the absorbance at 396 nm and 564 nm was linearly proportional to the IgGh concentration on a range from 0 to 200 ng mL-1, with a detection limit of 25 ng mL-1. The colorimetric method showed good selectivity for IgGh detection. It was possible to adapt the method to the determination of other proteins, such as factor IX. In another approach, anti-aptamer ATP was used to develop a colorimetric method for the determination of ATP based on stabilization of gold nanoparticles provided by strands of DNA.The strategy was based on stabilization of nanoparticles due to interaction with single strands of DNA, and the change of the stability of the nanoparticles provided by the conformational change of the aptamer following recognition. This method could in principle be used to detect analytes by substituting the aptamer used in this study by the specific aptamer for the target of interest

Malt lymphoma is a malignant disease that can arise in a variety of extra nodal sites. Previous studies indicate that tumour arise from more mature B-cells. Our purpose was to examine the presence of clonality and somatic hypermutation of immunoglobulin (IgVн) of MALT lymphomas. Paraffin-embedded tumour samples from13 MALT lymphoma were subjected to rearrangement analysis, by using PCR, heteroduplex gels and sequence analysis. Successful amplification was seen in 10/13 cases and sequences of IgVн genes were obtained in 6/13, all of them were mutated. The percentage of mutation compared to germline sequences was 1,1% to 8,6% monoclonal rearrangemang. It was demonstrated that 5 of 7 clones were derived from the Vн3 family, 2 from Vн1 and 1 from the Vн 4 family.

Allorecognition, defined as the ability to discriminate between self and non-self, is ubiquitous to colonial metazoans and widespread in aclonal taxa. Invertebrate allorecognition phenomena are of broad interest and have long captured the attention of geneticists by virtue of the allotypic diversity they display, marine ecologists by virtue of their control of effector mechanisms determining the outcome of intraspecific competition, evolutionary biologists by virtue of their regulation of the level at which selection acts, and immunologists by virtue of their resemblance to the allogeneic interactions that characterize pregnancy and transplantation in vertebrates. Diverse histocompatibility modes have been described in the jawed vertebrates, protochordates, and cnidarians, which are to date the only three taxa for which a genetic model to study allorecognition has been developed. Outside of the MHC-based histocompatibility of vertebrates, allorecognition determinants have been recognized in only two invertebrates. In the tunicate Botryllus, two genes involved in the histocompatibility response were characterized, FuHc and fester. In Hydractinia, the loci controlling allorecognition, alr1 and alr2, were mapped to a single chromosomal region, the allorecognition complex, and alr2 was recently identified as a polymorphic immunoglobulin superfamily (IgSF) receptor. In this study, the identification of the second Hydractinia allodeterminant, alr1, was undertaken. Chapter I briefly reviews prominent allorecognition model organisms and details the phenomenon in the model organism, Hydractinia symbiolongicarpus studied here. Chapter II describes the isolation of a 300.8 kb alr1-containing chromosomal interval by positional cloning. The analysis of that interval for its gene content and the determination of a primary alr1 candidate, CDS4, are described in Chapter III. Chapter III also reveals the existence of a complex of IgSF-like genes, to which belongs CDS4. CDS4, a novel polymorphic IgSF receptor that encodes a type I transmembrane protein with two hypervariable immunoglobulin-like extracellular domains, was confirmed to be the alr1 allodeterminant in Chapter IV, based on the investigation of natural polymorphism. CDS4 allele sequences were found to largely predict the outcome of allorecognition responses within and between laboratory lines and wild-type colonies, confirming the identity of CDS4 as the classically defined locus alr1. / Doctorat en sciences, Spécialisation biologie moléculaire / info:eu-repo/semantics/nonPublished

Orientador: Mateus José Rodrigues Paranhos da Costa / Resumo: Objetivou-se avaliar a eficácia do uso do colostro comercial em pó como substituto do colostro de vaca na primeira mamada de bezerras. Foram utilizadas 31 bezerras mestiças Holandês (H) x Gir (G), provenientes dos grupos genéticos 3/4HG, 5/8HG, 7/8HG e LA, divididas em dois grupos experimentais: G1 (n=15) 2L de colostro de vaca e G2 (n=16) 470g de colostro comercial em pó (SCCL, Saskatoon, SK, Canadá) diluídos em 1,5L de água morna, ambos fornecidos nas primeiras três horas de vida, e posteriormente recebendo mais 2L de colostro de vaca em até 12 horas após o nascimento. As concentrações de IgG presentes (p=0,006) foram maiores no colostro comercial em pó, enquanto as médias da β- caseína (p<0,0001), haptoglobina (p<0,0001) e α1-glicoproteína ácida (p=0,002) foram maiores nos colostros de vaca. As concentrações séricas de PT (G1 = 7,70 ± 1,00g/dL e G2 = 6,73 ± 0,65g/dL; p=0,003) e IgG (G1 = 2110,25 ± 595,03mg/dL e G2 = 1567,6 ± 418,25mg/dL; p=0,004) demonstraram diferenças estatísticas entre os grupos de manejo, com maiores médias para o G1. Houve diferenças significativas para a concentração de albumina sérica (p=0,005), com maiores médias para o G1 (4660,7 ± 384,61mg/dL). Não ocorreu diferença significativa para a haptoglobina sérica (p=0,29), porém suas concentrações médias se apresentaram bem mais altas em ambos os grupos de manejo (G1 = 33,86 ± 4,90 e G2 = 29,31 ± 5,63mg/dL). As enfermidades com maior ocorrência foram diarreia e pneumonia, sendo registrados também casos ... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: The purpose of this study was value the effectiveness in commercial colostrum powder using as a cow colostrum substitute in the first calf suckling. Twenty-one Holstein (H) x Gir (G) crossbred calves from 3/4HG, 5/8HG, 7/8HG and LA genetic groups were divided into two experimental groups: G1 (n = 15) 2L of cow colostrum and G2 (n = 16) 470g of commercial powdered colostrum (SCCL, Saskatoon, SK, Canada) diluted in 1.5L of warm water, both supplied within the first three hours of life, and subsequently receiving an additional 2L of cow colostrum in up to 12 hours after birth. Present IgG concentrations (p = 0.006) were higher in commercial powdered colostrum, while mean β-casein (p < 0.0001), haptoglobin (p <0.0001) and α1-acid glycoprotein (p = 0.002) were higher in cow colostrums. Serum concentrations of PT (G1 = 7.70 ± 1.00 g/dL and G2 = 6.73 ± 0.65 g/dL; p = 0.003) and IgG (G1 = 2110.25 ± 595.03 mg/dL and G2 = 1567.6 ± 418.25 mg/dL; p = 0.004) demonstrated statistical differences between management groups, with higher means for G1. There were significant differences in serum albumin concentration (p = 0.005), with higher means for G1 (4660.7 ± 384.61mg / dL). There was no significant difference for serum haptoglobin (p = 0.29), but its mean concentrations were much higher in both management groups (G1 = 33.86 ± 4.90 and G2 = 29.31 ± 5.63 mg/dL). The most common diseases were diarrhea and pneumonia, with cases of parasitic sadness and omphalitis, and two deaths in G2. Althou... (Complete abstract click electronic access below) / Mestre

La néphropathie à IgA (IgAN), est une maladie glomérulaire chronique primitive et principale cause d'insuffisance rénale dans le monde. Les causes et les facteurs aboutissant aux dépôts des complexes d'IgA1 sont inconnus. La forme soluble du récepteur (CD89s) complexée aux IgA joue un rôle clé dans la pathogenèse de cette maladie. Actuellement, aucun traitement spécifique n'est disponible et les options thérapeutiques sont limitées. La compréhension des mécanismes de la formation de ces complexes permettra d'envisager de nouvelles approches thérapeutiques. Dans cette perspective la première partie de cette thèse, met en évidence l'implication d'une protéine essentielle au développement de la N-IgA, la TG2, dans la régulation du clivage du CD89, et cela par la répression de la sérine phosphatase PP2A et l'activation de la métalloprotéase matricielle MMP-9. Dans les monocytes de patients l'expression diminuée de PP2A est associée à une tendance à l'augmentation de TG2, et inversement corrélée avec l'augmentation des complexes IgA1-CD89s. Afin de cibler ces complexes pathogéniques, un essai préclinique a été réalisé avec une protéase recombinante d'origine bactérienne clivant spécifiquement les IgA1 (IgA1-P). Les résultats ont formellement démontré la spécificité et l'efficacité de la protéase dans la réduction des complexes circulants et des dépôts d'IgA1 dans le modèle humanisé de N-IgA, associée à une diminution des marqueurs de l'inflammation et de l'hématurie. Les résultats ont mis en évidence le rôle de la dérégulation de l'axe TG2-PP2A-MMP-9 dans la formation des complexes IgA1-CD89s lors de la N-IgA, ainsi que l'efficacité de l'IgA1-P à éliminer ces complexes. Ces travaux suggèrent en plus du potentiel thérapeutique promoteur de l'IgA1-P, trois éventuelles cibles thérapeutiques envisageables pour la N-IgA. / IgA nephropathy (IgAN) is a mesangial proliferative primary glomerulonephritis and a major cause of end-stage renal disease. Causes and factors leading to mesangial IgA1 deposition are unknown. The soluble form of the receptor (sCD89) complexed with IgA plays a key role in the pathogenesis of the disease. There is currently no specific treatment available and the therapeutic options are limited. A better comprehension of the mechanisms regulating the formation of IgA1-sCD89 complexes will unveil new strategies for targeted therapies. In this perspective, the first part of this thesis highlights the implication of the transglutaminase 2 (TG2), a protein essential for the development of IgAN, in the regulation of CD89 cleavage, in a mechanism involving the repression of the serine phosphatase PP2A and the activation of the matrix metalloproteinase MMP-9. While a trend towards TG2 increase is observed, PP2A expression is reduced in monocytes obtained from IgAN patients compared to controls, and inversely correlates with the levels of circulating hIgA1-sCD89 complexes. In order to target these pathogenic complexes, a preclinical assay has been performed with a recombinant protease, a bacterial protein that selectively cleaves human IgA1 (IgA1-P). Results formally demonstrate the specificity and the efficacy of the IgA1-P in the reduction of circulating complexes and mesangial IgA1 deposition in a humanized mouse model of IgAN, associated with a reduction in inflammation and hematuria. Concluding, the results presented in this thesis show a role for the TG2-PP2A-MMP-9 axis in the dysregulated formation of IgA1-sCD89 complexes during IgAN development, as well as the effectiveness of IgA1-P in the elimination of these complexes. In addition to the potential therapeutic use of IgA1-P, this work suggests the TG2-PP2A-MMP-9 axis as a new therapeutic candidate for IgAN treatment.

C1q is the first subcomponent of the classical pathway of the complement system and a major connecting link between innate and acquired immunity. As a versatile charge pattern recognition molecule, C1q is capable of engaging a broad range of ligands via its heterotrimeric globular domain (gC1q) which is composed of the C-terminal regions of its A (ghA), B (ghB) and C (ghC) chains. Recent studies using recombinant forms of ghA, ghB and ghC have suggested that the gC1q domain has a modular organization and each chain can have differential ligand specificity. The crystal structure of the gC1q, molecular modeling and protein engineering studies have combined to illustrate how modular organization, charge distribution and the spatial orientation of the heterotrimeric assembly offer versatility of ligand recognition to C1q. Although the biochemical and structural studies have provided novel insights into the structure-function relationships within the gC1q domain, they have also raised many unexpected issues for debate.

Protein aggregation is deleterious to human health and detrimental to therapeutic shelf-life. The physical processes that induce aggregation are the same processes that drive productive folding reactions. As such, protein aggregation is a non-productive form of protein folding. To gain insight into the steps that serve as a partition between the folding and aggregation reactions, the folding mechanisms of several β-rich proteins with links to human disease or medicine were examined. In the ALS-linked protein, SOD1, a subpopulation of the unfolded ensemble is found to be a common source of both nonnative structure and frustrated folding. These behaviors are only observed upon the reduction of the intrinsic disulfide bond, indicating that this covalent interaction wards against aggregation. The nonnative structure presents an attractive target for the development of new therapeutic agents. In VH domains from therapeutic mAbs, the intramolecular disulfide bond protects against aggregation. However, it can also introduce complexity to the folding mechanism. This complexity is linked to the formation of a strained orientation of the disulfide bond. This strained orientation of the disulfide in certain VH domains is energetically unfavorable enough to disrupt the formation of the disulfide in the full length mAbs. The novel relationship observed between disulfide orientation, folding complexity, and incomplete oxidation warrants further examination in other Ig domains. Overall, these results demonstrate that mapping the folding free energy landscape for proteins with roles in human disease or therapeutics can provide valuable insights for developing and improving treatment options.

Induction of germline (GL) ε transcripts, an essential step preceding immunoglobulin (Ig) isotype switching to IgE, requires activation of transcription factors by IL-4 and a B cell activator, e.g. CD40 ligand (CD40L). AP-1 (Fos and Jun), induced transiently by CD40L, binds a DNA element in the mouse GL ε promoter. AP-1 synergizes with Stat6 to activate both the intact GL ε promoter and a minimal heterologous promoter driven by the AP-1 and Stat6 sites of the mouse GL ε promoter. By contrast, C/EBPβ, which transactivates the human GL ε promoter, inhibits IL-4 induction of the mouse promoter, probably by attenuating the synergistic interaction between AP-1 and Stat6. Furthermore, AP-1 does not transactivate the human GL ε promoter. Thus, due to selective binding of either AP-1 or C/EBP proteins, induction of GL ε transcripts in mouse and human may be regulated differently. In addition to AP-1, NF-кB activity is also induced by CD40L stimulation in normal B cells. Using GST pulldown assays and coimmunoprecipitation techniques I show that NF-кB and tyrosine-phosphorylated Stat6 can directly bind each other in vitro and in vivo. When Stat6 and NF-кB proteins are co-expressed in human embryonic kidney 293 (HEK 293) cells, an IL-4-inducible reporter gene containing both cognate binding sites in the promoter is synergistically activated in the presence of IL-4. Furthermore, the same IL-4-inducible reporter gene is also synergistically activated by the endogenous Stat6 and NF-кB proteins in IL-4-stimulated B lymphoma cells I.29μ. Consistently, by using nuclear extracts from transfected HEK 293 cells and from I.29μ B cells in electrophoretic mobility shift assays (EMSAs), I show that Stat6 and NF-кB bind cooperatively to a DNA probe containing both sites, and the presence of a complex formed by their cooperative binding correlates with the synergistic activation of the promoter by Stat6 and NF-кB. I conclude that the direct interaction between Stat6 and NF-кB may provide the basis for synergistic activation of the GL ε promoter. Finally, although mouse GL ε transcripts have a half-life of approximately 100 min, the RNA level continues to increase for up to 24 h and the promoter appears to be active for at least 2 days after B cell activation. These data suggest that induction of AP-1 and NF-кB activities by CD40L, although transient, is required for activation of the mouse GL ε promoter by IL-4-induced Stat6.

Cytokine induced transcription of the germline immunoglobulin heavy chain gene directs isotype switch recombination to that gene. Therefore, understanding the regulation of germline transcription is an important first step in understanding the class switching process. Treatment of human B cells with IL-4 results in germline epsilon transcription. Subsequent activation of a second signal is necessary for these cells to undergo class switch recombination and express surface IgE. In contrast, treatment of splenic murine B-cells with IL-4 alone does not induce germline epsilon transcription. However, treatment with IL-4 plus LPS does induces germline epsilon transcription, followed by class switching to the IgE isotype. In both human and mouse, IL-4 is absolutely required for induction of germline transcripts and expression of IgE. Therefore, IL-4 is considered to be an IgE switch factor. The murine B lymphoma line, I.29μ is an IgM+ B cell line which can be induced to switch to the IgE isotype by treatment with IL-4 plus LPS. In these cells, germline epsilon transcription is constitutive and can be further induced 5-20 fold with IL-4, whereas LPS has no effect at the RNA level. Thus, the I.29μ cell line provides a model system to study the regulatory effects of IL-4 on the murine germline epsilon promoter. The aim of this thesis is to characterize the murine germline epsilon promoter and identify the minimal DNA elements necessary and sufficient for IL-4 induction. To identify the promoter elements, two kb of the 5' flanking region to the first exon (Iε) of the germline epsilon transcript was cloned into a Luciferase reporter plasmid and assayed for promoter activity. Assay of successive 5' deletion mutations by transfections into two B cell lines, I.29μ and M12.4.1, identified the 213 bp promoter construct, -162Luc, as containing sufficient sequence to confer full promoter function. Assay of the linker scanning mutations in the -162Luc plasmid localized the IL-4 responsive effect to a 46 bp region of the promoter. This region contains three nuclear factor binding elements: a C/EBP site, a recently identified NF-IL-4 site and a NFкB/p50 site. In order to detect protein complexes that specifically interact with this active region of DNA, electrophoretic mobility shift assays were performed using double stranded, oligonucleotide probes of this IL-4 responsive region. An IL-4 inducible complex was identified in nuclear extracts of I.29μ as well as murine splenic B-cells. Competition experiments with mutant probes mapped this inducible complex to the NF-IL-4 site. Constitutive binding of both C/EBP and NFкB/p50 was demonstrated by cold competition and supershift experiments. Transfection experiments using a series of linker scanning mutations allowed identification of DNA elements necessary for IL-4 induction. In order to test if these elements are sufficent for IL-4 induction, double stranded oligonucleotides containing these elements were transfered to a minimal fos promoter plasmid and assayed for IL-4 responsiveness. A 27 bp fragment containing two DNA elements, a C/EBP and a NF-IL-4 site were sufficient to confer IL-4 inducibility to a minimal c-fos promoter. This study defined a different IL-4 response element in the murine germline epsilon promoter from that previously published. This IL-4 response element is identical to the IL-4 response element in the human germline epsilon promoter. The NF-IL-4 site is also present in the promoter of the IL-4 responsive gene, CD23b (FcεRII), and this element binds an IL-4 inducible complex present in the human monocytic cell line U937. Various reports demonstrate the presence of an IL-4 inducible complex by gel shift assays and indeed the binding activity of NF-IL-4 has been mapped to a 9 bp consensus sequence within a 19 bp fragment. However, the transfer of IL-4 inducibility has not been reported using fragments smaller than 123 bp, the importance of which is underscored by the fact that more than one factor is involved in this induction. The contribution of this thesis to the understanding of transcriptional induction by IL-4 is in the delineation of the factors involved - namely, a member of the C/EBP family and NF-IL-4 are required for IL-4 induction and NFкB/p5O modulates this induction.

Proteins, which are T cell-dependent antigens, preferentially induce antibodies of the IgG1 class in mouse, whereas LPS, which is a T-independent antigen, preferentially induces IgG3 and IgG2b. Interaction between CD40 on B cells and CD40 ligand (CD40L) on T cells has been shown to mediate T cell contact help for B cell proliferation, differentiation and immunoglobulin isotype switching. In addition, it has been shown that membranes from activated T cells induce germline γ1 transcripts, and that CD40 signaling induces germline γ1 transcripts. These results indicate that T cell contact help mediated by CD40 ligand (CD40L)-CD40 interaction may contribute to this preferential IgG1 isotype selection in response to T-dependent antigens by inducing transcription of germline Ig γ1 transcripts. Here we show that signaling via CD40 increases expression of a transiently transfected luciferase reporter plasmid driven by the germline γ1 promoter in M12.4.1 B lymphoma cells. By linker scanning mutation analysis of the promoter, we have identified a CD40 responsive region (CD40RR) which is able to confer inducibility by CD40L to a minimal c-fos promoter. The CD40RR contains three NF-кB-binding sites, each of which is required for maximal induction of the γ1 promoter activity by CD40L. Binding of the NF-кB/Re1 proteins p50, Re1A, c-Re1 and Re1B to the CD40RR can be induced by CD40 signaling in M12.4.1 cells or in splenic B cells. Co-transfection of expression plasmids for p50 together with Re1A or Re1B, but not p50 alone or p50 and c-Re1, transactivates the CD40RR in transient transfection assays in M12.4.1 cells. These data demonstrate NFкB/Re1 proteins activated by CD40 engagement play an important role in regulation of the germline γ1 promoter. Further support for this conclusion is provided by the finding that treatment of splenic B cells with NF-кB inhibitors prevents induction of germline γ1 transcripts by CD40L. Although LPS also induces NF-кB activation, it poorly induces germline γ1 promoter activity in M12.4.1 cells and it also poorly induces germline γ1 transcripts in splenic B cells and in the mouse B cell line, 1B4.B6. Western blot analyses show that LPS predominantly activates p50 and c-Re1, whereas CD40L induces all NF-кB/Re1 proteins (Re1A, Re1B, c-Re1 and p50). Likewise, in nuclear extracts from LPS-treated cells, p50/cRe1 and p50/p50 dimers are the major NF-кB/Re1 proteins which bind to the promoter for germline γ1 transcripts in electrophoretic mobility shift assays, whereas in nuclear extracts from CD40L-treated cells, p50/Re1A and p50/Re1B dimers are the major complexes. Reporter gene assay by over expressing NF-кB/Re1 fusion proteins indicates that p50/Re1A and p50/Re1B dimers, but not p50/c-Re1 or p50/p50 dimer, can transactivate the germline γ1 promoter. Despite their inability to activate the promoter, p50/c-Re1 and p50/p50 can bind to the promoter and suppress the transactivation activity of p50/Re1A and p50/Re1B. Therefore, the effect of NF-кB activation on the germline γ1 promoter depends on the Relative amounts of transactivating and non-trans activating NF-кB/Re1 dimers. The inability of LPS to induce germline γ1 transcripts can be explained by induction of non-transactivating NF-кB/Re1 dimers and the ability of CD40L to activate the promoter by a greater induction of Re1A and Re1B Re1ative to c-Re1.